Warfarin has long been the most widely prescribed oral anticoagulant. Introduction of non-vitamin K oral anticoagulants (NOACs) has provided anticoagulant options but also presented the potential challenge of transitioning between agents. Changes from NOACs to warfarin are particularly problematic with delays to therapeutic effect and limited real-world data regarding the impact on warfarin control. The aim of this study was to investigate the frequency of switching anticoagulants and the effect on warfarin control. Retrospective data was collected for patients at a warfarin program in Queensland Australia who had exited the program for NOACs plus those who had reverted to warfarin. Data included documented reasons for change and International Normalised Ratio (INR) results with time in therapeutic range (TTR) calculated as a measure of warfarin control. Over 5 years, a total of 3036 patients ceased warfarin to commence a NOAC but 142 (4.7%) reverted to warfarin. Majority of patients (60.6%) reverted to warfarin within 6 months of trialling NOACs with a median of 6 days to therapeutic INR. There was no significant difference in warfarin control before changing to NOACs and after reverting to warfarin (mean TTR 75%) but significantly more frequent testing and lower doses were required to achieve this control. Transitions from warfarin to NOACs results in almost a week to therapeutic effect and warfarin therapy may be further complicated by a need for increased frequency of testing. Further studies are required to refine transition strategies particularly from warfarin to NOAC and minimise potential risks to patients.
Highlights
• Although many warfarin patients are being switched to alternate anticoagulants, almost 5% of these patients revert back to warfarin with the majority (61%) reverting within six months • Patients switching from alternate anticoagulants to warfarin have a median time to first INR in range of 6 days with 96.2% of patients having at least one INR in range by 30 days • Significantly more frequent testing and significantly lower doses are required to achieve previous levels of warfarin control which may further complicate warfarin therapy • Further studies regarding transition strategies particularly from warfarin to NOAC are required to minimise potential risks to patients
Introduction
Warfarin has long been the oral anticoagulant used in the treatment and prevention of thromboembolic disease [1] . Warfarin's narrow therapeutic index and individualised response necessitates frequent monitoring of the international normalised ratio (INR), with time in therapeutic range (TTR) a commonly used measure of warfarin control [1] . Concerns regarding warfarin including monitoring requirements, inadequate TTR, bleed risk and underuse in patients eligible for anticoagulation, has led to the development of non-vitamin K oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban [2] . Meta-analyses of the large comparative trials of the NOACs in non-valvular atrial fibrillation (AF) patients have demonstrated them to be slightly superior to warfarin in stroke and systemic embolism and associated with lower risk for intracranial haemorrhage [2] . The availability of the NOACs has given prescribers choice between oral anticoagulants and the potential challenge of transitioning between warfarin and individual NOACs [3] . In 2017, Hellfritzsch et al. [4] found 46.5% of anticoagulant users had experienced one or more treatment changes with transitions from warfarin to NOAC more common than NOAC to warfarin. Transitions from NOAC to warfarin are particularly troublesome due to fluctuating INRs during introduction and delays in reaching target INR [3] . However, there has been limited data on warfarin control in real-world patients changing between NOACs and warfarin. Therefore, the aim of this study was to investigate the frequency of changing oral anticoagulant therapies and the effect on warfarin control, particularly in patients changing to a NOAC then reverting back to warfarin.
Methods
Ethics approval was obtained-Griffith University PHM/09/14/HREC. A retrospective analysis was conducted for patients enrolled in a warfarin program at a private pathology practice in Queensland between June 2012 and July 2017. The warfarin management program is available to any patient taking warfarin referred by their general practitioner with the service including blood collection, laboratory testing, result interpretation and dose instruction by specialist general practitioners, and information regarding subsequent follow-up provided by nurses or trained staff. Patients who had exited the program for a NOAC together with patients who had reverted to warfarin after a NOAC were identified. Documented reasons for changes were recorded together with INR results and warfarin doses for patients reverting to warfarin therapy. TTR was calculated using the Rosendaal method [5] with software downloaded from INRPro© with patients excluded from TTR analysis if there were insufficient tests to calculated TTR or less than 30 days of therapy before or after changes. Mean patient data was used for analysis and comparison of warfarin control before and after NOAC therapy via paired nonparametric tests using GraphPad Instat Version 3.
Results
From June 2012 to July 2017, a total of 3036 patients exited the warfarin program to commence a NOAC with the highest percentage (47.6%) in 2013-2014 (Table 1) . The majority of patients changed to rivaroxaban (61.6%), followed by apixaban (25.6%), and dabigatran (12.8%). Of the 3036 patients changing to a NOAC, a total of 142 (4.7%) patients reverted to warfarin therapy with the majority of patients (60.6%) reverting to warfarin less than 6 months after commencing a NOAC.
Of the 142 patients that reverted to warfarin, a total of 131 patients were analysed for warfarin control following exclusions. After changing from NOAC to warfarin, the median time to first INR in range was 6 days and 96.2% of patients had at least one INR in range by 30 days. Before changing to a NOAC and after reverting to warfarin there was no significant difference in mean TTR (74.6 ± 15.5% vs 75.6 ± 13.4% respectively) but the frequency of testing was significantly different (13.7 ± 5.4 days vs 12.7 ± 7.0 days, p = 0.0075 respectively) as was the average daily dose (4.5 ± 2.0 mg vs 4.1 ± 2.1 mg, p < 0.0001 respectively).
Discussion
There is now a choice between oral anticoagulants and potential for transitions between agents but there is limited real-world data on the frequency of switching and warfarin control in this transition period. The aim of this study was to determine the frequency of changing oral anticoagulant therapies and the impact on warfarin control. This study found that after changing to a NOAC, almost 5% of patients revert to warfarin with a median time to first INR in range of 6 days and 96.2% of patients having at least one INR in range by 30 days. Warfarin control was not significantly different before changing to a NOAC and after reverting to warfarin (mean TTR 75%), however significantly more frequent testing and significantly lower doses were required to achieve this TTR.
In Australia, warfarin remains the most widely prescribed oral anticoagulant but use has declined since introduction of the NOACs [6] . An analysis of Australian prescribing estimated that in 2013-2014 up to 53% of patients prescribed NOACs had previously used warfarin but this declined to 24% the following year [6] . Similar to this, our study found that almost 48% of patients were converted to NOACs in 2013-2014 with rates declining to approximately 16% in subsequent years. Over the study period the percentage of patients changing to rivaroxaban decreased whilst changes to apixaban increased which is consistent with Hale et al. [7] who reported increased percentages of patients on warfarin changing to apixaban.
Hellfritzsch et al. [4] estimated that 1 in 3 NOAC users had changed from a vitamin K antagonist but also found approximately 10% of NOAC initiators had reverted to warfarin within 1 year. Hale et al. [7] reported about 13% of patients changing from warfarin to a NOAC reverted to warfarin. In contrast to these studies, we reported a lower rate of reverting to warfarin of 4.7%. Our study was conducted in a specialist warfarin management program and only included patients both recommencing warfarin and returning to the program thus potentially under-estimated patients reverting to warfarin as patients may have recommenced warfarin but remained managed by their general practitioner. The majority of patients in our study returned to warfarin therapy less than 6 months after commencing a NOAC with the reason in 23% of patients being intolerance. Similar to this, Hale et al. [7] found roughly half of their patients reverted back to warfarin within 6 months of NOACs with the most common reasons being side effects (21.2%) or clotting events (17.3%). Interestingly, in our study a more common reason for returning to warfarin from a NOAC were bleeds (9.3%) rather than thromboembolic events (2.8%). However, this is consistent with Hellfritzsch et al. [8] who found bleeds more frequent than thromboembolic events in patients who discontinued NOACs. The large comparative trials of NOACs and warfarin had structured transitions to warfarin [9, 10] . Mahaffey et al. [9] reported a median time to first INR in range of 13 days in patients reverting to warfarin from rivaroxaban, whilst Ruff et al. [10] found a lower median of 9 days to therapeutic INR in patients reverting to warfarin from edoxaban. Our study compares favourably to this with a median of 6 days to first INR in range. Similarly, we found 96% of patients with at least one INR ≥ 2 by 30 days which is superior to the 52% [9] and comparable to the 99% [10] reported from these studies. Australian guidelines [11] recommend transitioning from NOAC to warfarin with specialist consultation as INR results can be affected by both the NOAC and warfarin and thus the interpretation of INR and time to cease NOAC is dependent on the baseline INR of individual patients. This study did not investigate factors such as baseline INR before transitioning or other factors such as renal function or protein C & S levels which may have influenced the transition between NOAC and warfarin. Future research should investigate such factors to further investigate INR stability and the potential for any increased risk of bleeds or thrombosis at this time.
Hale et al. [7] identified unstable INR was the most common reason for a change from warfarin to a NOAC with a mean TTR of 54% at the time of changing. In our study the mean TTR of patients changing to NOACs was almost 75% with only around 20% of these patients having TTR levels below 65%. In 2014, the Australasian Society of Thrombosis and Haemostasis suggested patients stably anticoagulated on warfarin (i.e. TTR > 65% over 3 month period) are least suitable for NOACs [12] . Using the TTR < 65% criteria for changing from warfarin, it could be argued that 80% of these patients were not suitable candidates for a change from warfarin. However, a previous study of the same warfarin program found a mean TTR of 81% with less than 3% of patients with a TTR < 60% [13] suggesting slightly lower control in patients changed to NOAC. Interestingly Pokorney and Granger [14] found data does not support a substantially larger benefit of NOACs in patients with poor warfarin control but found a modest absolute benefit from NOACs in patients naïve to oral anticoagulants. Further studies are required to identify the subset of existing warfarin patients that would particularly benefit from changing to NOACs especially in the Australian context with relatively high levels of warfarin control reported.
In our study, patients reverting to warfarin obtained no significant difference in TTR but required significantly more frequent testing to achieve this. Arnsten et al. [15] found noncompliant patients on warfarin considered frequent blood tests to be a major problem to warfarin use. The increased frequency of testing required when returning to warfarin could further contribute to perceived concerns regarding INR testing. In our study, significantly lower doses were also required when reverting to warfarin to achieve the 75% TTR. Leonhard et al. [16] found 64% of patients on warfarin were reinitiated on lower doses after temporary discontinuation but could not associate the dosing with specific patient factors. A number of genetic and clinical factors are known to influence dose requirements including age, race, and medications [1] so further investigation is needed to determine if the lower doses seen when recommencing warfarin can be explained by these patient factors.
In conclusion, this study found that whilst many patients on warfarin are changing to NOACs, approximately 5% of these are reverting to warfarin with a median of 6 days before obtaining therapeutic INR and more frequent testing required to achieve previous TTR levels. Further studies are required to refine transition strategies particularly from warfarin to NOAC to minimise potential risks to patients.
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